植入物重建术后乳房切除术后放疗的大分割对比常规分割:一项随机临床试验
这项随机临床试验在16个美国癌症中心纳入400例接受乳房切除及即刻扩张器或植入物重建后单侧PMRT的患者,1:1随机接受大分割或常规分割放疗。主要终点为6个月时FACT-B躯体健康维度变化,两组无显著差异(估计值0.13;95%CI -0.86至1.11;P=0.80),但年龄组与治疗组存在显著交互作用(交互P=0.03)。
要点
- 大分割与常规分割PMRT在6个月FACT-B躯体健康维度变化上无显著差异。
- 年龄组与治疗组存在显著交互作用(交互P=0.03),<45岁患者大分割组6个月绝对PWB评分更高。
- 胸壁毒性反应在大分割组与常规分割组间无显著差异(HR 1.02;95%CI 0.52-2.00;P=0.95)。
核心结论
- 在本随机临床试验中,大分割方案与常规分割方案相比未显著改善躯体健康维度的变化。
- 这些数据为植入物重建患者接受大分割PMRT增加了不断积累的经验。
研究设计与样本
- 随机临床试验,于2018年3月8日至2021年11月3日在16个美国癌症中心或医院纳入400例18岁及以上接受乳房切除及即刻扩张器或植入物重建、Tis、TX或T1-3期乳腺癌并接受单侧PMRT的患者。
- 患者1:1随机分配至大分割或常规分割PMRT组(常规分割组201例,大分割组199例;中位年龄47岁,范围23-79岁)。
- 中位随访40.4个月(范围15.4-63.0个月),分析于2023年9月至12月进行。
主要发现
- 400例患者中330例有基线和6个月时PWB评分;两组PWB变化无差异(估计值0.13;95%CI -0.86至1.11;P=0.80)。
- 年龄组与研究臂存在显著交互作用(交互P=0.03);<45岁患者中,大分割组6个月绝对PWB评分高于常规分割组(23.6 [95%CI 22.7-24.6] vs 22.0 [95%CI 20.7-23.3];P=0.047)。
- 不良反应困扰程度均值(SD)大分割组为3.0(0.9),常规分割组为2.6(1.2)(P=0.02);恶心均值(SD)大分割组为3.8(0.4),常规分割组为3.6(0.8)(P=0.04)。
- 按治疗分析队列中,远处复发23例(大分割组11例,常规分割组12例),局部区域复发2例(大分割组1例,常规分割组1例)。
- 胸壁毒性反应39例(大分割组20例,常规分割组19例),中位(IQR)发生时间7.2(1.8-12.9)个月;多因素分析中分割方式与胸壁毒性无关(大分割组:风险比1.02;95%CI 0.52-2.00;P=0.95)。
关键数值与推荐
- 胸壁剂量:大分割组4256 cGy分16次;常规分割组5000 cGy分25次。
- 胸壁毒性反应定义为3级或以上不良事件。
- 主要终点为开始PMRT后6个月时FACT-B躯体健康维度变化,控制年龄。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Postmastectomy radiation therapy (PMRT) improves local-regional disease control and patient survival. Hypofractionation (HF) regimens have comparable efficacy and complication rates with improved quality of life compared with conventional fractionation (CF) schedules. However, the use of HF after mastectomy in patients undergoing breast reconstruction has not been prospectively examined. OBJECTIVE: To compare HF and CF PMRT outcomes after implant-based reconstruction. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial assessed patients 18 years or older undergoing mastectomy and immediate expander or implant reconstruction for breast cancer (Tis, TX, or T1-3) and unilateral PMRT from March 8, 2018, to November 3, 2021 (median [range] follow-up, 40.4 [15.4-63.0] months), at 16 US cancer centers or hospitals. Analyses were conducted between September and December 2023. INTERVENTIONS: Patients were randomized 1:1 to HF or CF PMRT. Chest wall doses were 4256 cGy for 16 fractions for HF and 5000 cGy for 25 fractions for CF. Chest wall toxic effects were defined as a grade 3 or higher adverse event. MAIN OUTCOMES AND MEASURES: The primary outcome was the change in physical well-being (PWB) domain of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality-of-life assessment tool at 6 months after starting PMRT, controlling for age. Secondary outcomes included toxic effects and cancer recurrence. RESULTS: Of 400 women (201 in the CF arm and 199 in the HF arm; median [range] age, 47 [23-79] years), 330 patients had PWB scores at baseline and at 6 months. There was no difference in the change in PWB between the study arms (estimate, 0.13; 95% CI, -0.86 to 1.11; P = .80), but there was a significant interaction between age group and study arm (P = .03 for interaction). Patients younger than 45 years had higher 6-month absolute PWB scores if treated with HF rather than CF regimens (23.6 [95% CI, 22.7-24.6] vs 22.0 [95% CI, 20.7-23.3]; P = .047) and reported being less bothered by adverse effects (mean [SD], 3.0 [0.9] in the HF arm and 2.6 [1.2] in the CF arm; P = .02) or nausea (mean [SD], 3.8 [0.4] in the HF arm and 3.6 [0.8] in the CF arm; P = .04). In the as-treated cohort, there were 23 distant (11 in the HF arm and 12 in the CF arm) and 2 local-regional (1 in the HF arm and 1 in the CF arm) recurrences. Chest wall toxic effects occurred in 39 patients (20 in the HF arm and 19 in the CF arm) at a median (IQR) of 7.2 (1.8-12.9) months. Fractionation was not associated with chest wall toxic effects on multivariate analysis (HF arm: hazard ratio, 1.02; 95% CI, 0.52-2.00; P = .95). Fewer patients undergoing HF vs CF regimens had a treatment break (5 [2.7%] vs 15 [7.7%]; P = .03) or required unpaid time off from work (17 [8.5%] vs 34 [16.9%]; P = .02). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the HF regimen did not significantly improve change in PWB compared with the CF regimen. These data add to the increasing experience with HF PMRT in patients with implant-based reconstruction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03422003.
引用
- Wong JS, Uno H, Tramontano AC, et al. Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 39115975. doi:10.1001/jamaoncol.2024.2652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。